scholarly journals Combination of DCE-MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Changmin Liu ◽  
Roger Sun ◽  
Jing Wang ◽  
Fangling Ning ◽  
Zhenbo Wang ◽  
...  
Keyword(s):  
Esophageal Carcinoma ◽  
Diagnostic Performance ◽  
Model Comparison ◽  
Roc Analysis ◽  
Concurrent Chemoradiotherapy ◽  
Extracellular Fluid ◽  
Response To Treatment ◽  
Transfer Constant ◽  
Dce Mri ◽  
Mri Scans

Background. Concurrent chemoradiotherapy (CCRT) is the main treatment for esophageal cancer, but the response to treatment varies from individual to individual. MR imaging methods, such as diffusion-weighted (DW) MRI and the use of dynamic contrast-enhanced (DCE) MRI, have the potential to provide additional biomarkers that could evaluate the effect of CCRT in patients with esophageal carcinoma. Materials and Methods. Fifty-six patients with esophageal carcinoma, verified by histopathology, underwent MRI examination before and at midtreatment (4th week, radiotherapy 30–40 Gy) using the Siemens 3.0 T MR System. Parameter maps of apparent diffusion coefficient (ADC), and DCE maps of volume transfer constant (Krans), rate contrast (kep), and extracellular fluid space (ve), were computed using a Siemens Company Multimodality Workplace (MMWP) model. Comparison of histogram parameters and their diagnostic performance was determined using the Mann–Whitney U test and receiver operating characteristic (ROC) analysis. Results. 56 patient MRI scans were available for analysis at baseline and at the third week, respectively. Pretreatment Krans, pretreatment kep, pretreatment ADC (P<0.05), and during-treatment Krans (P<0.05) and ΔKrans and ΔADC (P<0.05) were significantly different after CCRT. Based on the binary logistic model, the ROC analysis demonstrated that the combined predictors demonstrated a high diagnostic performance with an AUC of 0.939. The sensitivity and specificity were 98.6% and 73.8%, respectively. Conclusion. The combination of DCE and DWI can be used as an early biomarker in the prediction of the effect of CCRT three weeks after treatment in esophageal carcinoma.

Dynamic contrast enhanced MRI (DCE MRI) for assessment of effects of anti-angiogenic therapy: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameters model

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14109-14109 ◽  
Author(s):  
C. H. Thng ◽  
T. S. Koh ◽  
H. Rumpel ◽  
J. B. Khoo ◽  
A. B. Ong ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Blood Flow ◽  
Phase I ◽  
Roc Analysis ◽  
Drug Exposure ◽  
Transfer Constant ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Distributed Parameters ◽  
Contrast Enhanced

14109 Background: Transfer constant (Ktrans) and IAUC60 normalized with arterial input function are commonly used dynamic contrast enhanced magnetic resonance imaging (DCE MRI) parameters. The distributed parameters model (DP) is a DCE MRI model that enables derivation of blood flow and capillary permeability-surface area product (PS). We aim to study the distributed parameters model as an alternative method of angiogenesis assessment and correlate the above parameters to drug exposure and patient outcome in a Phase I anti- angiogenic trial. Methods: Fifteen evaluable patients from an on-going Phase I trial (ABT 869) with 3 dose escalations formed the study population. Pharmacokinetic study was performed on Day 1 and the area under the concentration time curve extrapolated to infinity (AUCinfinity) was used as an indicator of drug exposure. All patients underwent DCE MRI at baseline, Day 3 and Day 15 with temporal resolution of 4 seconds. Gadolinium concentrations were estimated using a dual flip angle method. Patients demonstrating progressive disease in first 2 evaluation scans (cycle 2 or 4) based on RECIST criteria were considered progressors and all other patients non-progressors. Receiver operating curve (ROC) analysis was performed. Correlation with AUCinfinity was analyzed. Results: There is good correlation (Spearman’s coefficient -0.67, p = 0.008) between AUCinfinity and DP derived PS and less strong correlation with normalized IAUC60 (Spearman’s coefficient -0.57, p = 0.03). There is no correlation for Ktrans (Spearman’s coefficient 0.04). ROC analysis for predicting progressors versus non-progressors showed a higher ROC area for PS compared to Ktrans (0.83 versus 0.47, p = 0.037). Normalized IAUC60 showed a slightly lower area compared to PS (0.77 versus 0.83) but the difference is not significant (p = 0.58). Conclusions: PS derived from DP model shows better correlation with drug exposure and may predict patient outcome better than Ktrans. [Table: see text]

Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 613-613
Author(s):  
Khurum Hayat Khan ◽  
Mihaela Rata ◽  
Dow-Mu Koh ◽  
Nina Tunariu ◽  
George Vlachogiannis ◽  
...  
Keyword(s):  
Unmet Need ◽  
Predictive Biomarkers ◽  
Progression Free Survival ◽  
Target Lesion ◽  
Liquid Biopsies ◽  
Transfer Constant ◽  
Potential Health ◽  
Economic Implications ◽  
Dce Mri ◽  
Mri Scans

613 Background: REG demonstrated efficacy in pre-treated mCRC pts. Lack of predictive biomarkers, potential toxicities and cost/effectiveness concerns highlight the unmet need for better patient selection. Methods: RAS mutant mCRC pts with biopsiable metastases were enrolled in this phase II trial. Tissue biopsies (6-12 cores) were obtained at baseline (BL), after 2 months if stable disease (SD) and at disease progression (PD). Dynamic contrast enhanced (DCE) MRI was acquired pre and at day 15 post-treatment. Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) [K-trans*EF/100] were generated. Circulating tumour (ct)DNA was collected monthly until PD and tested for clonal RAS mutations by digital droplet PCR. PDOs derived from responders and non-responders pts were implanted orthotopically in the liver of mice and treated with REG for 5 days. Changes in tumour and fractional blood volume (fBV) were monitored by oxygen-enhanced MRI. Results: mCRC pts (n = 27) with paired MRI scans were analysed; a single target lesion per pt was chosen (25 liver and 2 pelvic metastases). Median K-trans*EF/100 product decrease was 58.2%. In the 23 analysable pts (4 received < 1 cycle of treatment due to toxicities), > 70% drop in K-trans*EF/100 (8/23) was associated with higher disease control rate (6/6 vs. 0/6, p = 0.048) measured by RECIST 1.1 at 2 months, improved progression free survival (PFS) [HR = 0.24 (0.07-0.86), p = 0.03], and 4-month PFS (58.3% VS 21.2%). Sequential tissue biopsies analysis confirmed reduction in CD31 in pts with K-trans*EF/100 drop. RAS mutant clones decay in ctDNA after 8 weeks of treatment was associated with better PFS [HR = 0.25 (0.08 - 0.83), p = 0.02] independently of K-trans*EF/100 drop. PDOs xeno-transplants treated with REG compared to controls had significant lower tumour fBV (4.5 VS 10.6, p = 0.03) and lower microvascular density measured by CD31 staining (4.3 VS 8.9, p = 0.02). Conclusions: Combining DCE MRI and ctDNA predicts depth and duration of anti-angiogenic response to REG monotherapy and may improve pt selection with potential health/economic implications. Clinical trial information: 201400357951.

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7676-7676 ◽  
Author(s):  
B. Morgan ◽  
M. A. Horsfield ◽  
J. Stattaus ◽  
A. Khalil ◽  
T. C. Gauler ◽  
...  
Keyword(s):  
Growth Factor Receptor ◽  
Stage Iv ◽  
Compartment Model ◽  
Response Assessment ◽  
Response To Treatment ◽  
Mri Imaging ◽  
Transfer Constant ◽  
Dce Mri ◽  
Disease Stabilization ◽  
The Difference

7676 Background: Overexpression of vascular endothelial growth factor receptor (VEGF-R) in NSCLC-tumors is linked to poor prognosis and shorter overall survival. PTK/ZK (PTK/ZK) is a novel, oral, anti-angiogenic compound blocking all currently known VEGF receptors (VEGF-R1–3). DCE-MRI measures early changes in tumour-associated vasculature in response to treatment and has been successfully used as a biomarker for biological activity of PTK/ZK in liver metastases from colorectal cancer. Methods: This is a prospective, multi- centre, phase-II study of PTK/ZK in pretreated patients with advanced stage NSCLC. 54 patients (pts) received 1,250 mg PTK/ZK once daily (qd), followed by 58 patients receiving 1,250 mg (500 am + 750 mg pm) PTK/ZK twice daily (bid). Response evaluation was based on RECIST. Disease stabilization of at least 12 weeks based on CT/MRI-imaging was defined as clinically relevant drug activity. DCE-MRI was performed 2- 4 hours after PTK/ZK administration, on day 2 and at day 28. Contrast enhancement for the whole tumour was assessed by calculating the transfer constant (Ktrans) using a two-compartment model. Results: DCE-MRI was performed successfully in 35 pts in the qd cohort on day 2 and 29 pts in the qd cohort at day 28. There was a statistically significant mean reduction in Ktrans at day 2 of 35.2 % (p<0.0001, N=35, paired ‘t’ test) and at Day 28 of 38.1% (p<0.0001, N=29). 32 pts with day 2 DCE- MRI were evaluable for response assessment with 10 (31%) achieving SD at 12 weeks and 22 (69%) with progressive disease (PD). Both the SD group and the PD group had significant mean reductions in Ktrans at day 2 (39.4% and 37.1%, respectively). However, the difference between SD and PD was not statistically significant. Data for the bid cohort will be presented at the meeting. Conclusions: PTK/ZK causes statistically significant reduction in tumour vascular parameters of lung tumours. Ktrans has previously been shown to correlate with clinical outcome. However, for the qd cohort, no correlation could be demonstrated. This may be due to the limitation of the sample size as well as the heterogeneity of the targeted lesions selected for this study. [Table: see text]

scholarly journals Comparing Low and High-Temporal Resolution DCE-MRI Texture Analysis for Discrimination of Breast Lesions from Background Enhancement

2020 ◽  
Author(s):  
Yufeng Liu ◽  
Jiaying Li ◽  
Jingjing Qu ◽  
Rui Tang ◽  
Kun Lv ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Temporal Resolution ◽  
Diagnostic Performance ◽  
Roc Analysis ◽  
Pharmacokinetic Parameters ◽  
High Temporal Resolution ◽  
Breast Lesions ◽  
Benign Lesions ◽  
Dce Mri ◽  
Background Enhancement

Abstract Background Breast cancer is the most common cancer in women worldwide, high-resolution dynamic contrast-enhanced MRI (DCE-MRI) can better evaluate the tissue microenvironment and texture characteristics. The purpose of this study was to investigate the value of the texture-based analysis for breast DCE-MRI in the diagnosis of breast lesions and background enhancement. Methods This study prospectively enrolled 128 patients with clinically suspected breast lesions in our hospital from April 2015 to June 2017. Among them, 62 patients underwent preoperative high temporal resolution DCE-MRI (1 + 26 phases) scan with 39 malignant and 23 benign lesions. The control group retrospectively and randomly contained 78 patients who underwent preoperative low temporal resolution DCE-MRI (1 + 5 phases) scans with 46 malignant and 32 benign lesions. Quantitative parameters were obtained using a two-compartment Extended Tofts and volume of interest model for the lesion center, surrounding peripheral area and background enhancement, including pharmacokinetic parameters (Ktrans, Kep, Ve and Vp) and texture features based on the Ktrans map. The Student’s t-test was used to compare the differences of means. LASSO was used for dimension reduction and logistic regression analysis was used for model construction. A receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance. Results Pharmacokinetic parameters were significantly different between high temporal resolution and low temporal resolution DCE-MRI (P < 0.05). In the malignant group, the average Ktrans of the lesion area on high temporal resolution DCE-MRI was significantly correlated to the pathological grading (r = 0.400, P = 0.012). In the differentiation between benign and malignant lesions, the ROC analysis demonstrated that the diagnostic value of high temporal resolution DCE-MRI offered slightly significant advantages in the realms of the lesion, peripheral areas and background enhancement. Conclusions The use of texture analysis based on high temporal resolution DCE-MRI may potentially improve breast cancer diagnostic performance. Specifically, combining the lesion, peripheral, BE area, and Ktrans-mean parameters can contribute to the diagnosis of breast lesions, background enhancement and the pathological grading of malignant tumors.

scholarly journals Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Wenbing Ji ◽  
Jian Wang ◽  
Rongzhen Zhou ◽  
Minke Wang ◽  
Weizhen Wang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Vascular Permeability ◽  
Diagnostic Performance ◽  
Neoadjuvant Chemoradiotherapy ◽  
Combined Model ◽  
Diagnostic Ability ◽  
Dce Mri ◽  
Texture Parameters ◽  
Mri Scans

BackgroundEsophageal squamous cell carcinoma (ESCC) is an aggressive type of cancer, associated with poor prognosis. The development of an accurate and non-invasive method to evaluate the pathologic response of patients with ESCC to chemoradiotherapy remains a critical issue. Therefore, the aim of this study was to assess the importance of vascular permeability and texture parameters in predicting the response to neoadjuvant chemoradiotherapy (NACRT) in patients with ESCC.MethodsThis prospective analysis included patients with T1–T2 stage of ESCC, without either lymphatic or metastasis, and distant metastasis. All patients underwent surgery having received two rounds of NACRT. All patients underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) twice, i.e., before the first NACRT and after the second NACRT. Patients were assessed for treatment response at 30 days after the second NACRT. Patients were divided into the complete response (CR) and partial response (PR) groups based on their responses to NACRT. Vascular permeability and texture parameters were extracted from the DCE-MRI scans. After assessing the diagnostic performance of individual parameters, a combined model with vascular permeability and texture parameters was generated to predict the response to NACRT.ResultsIn this study, the CR and PR groups included 16 patients each. The volume transfer constant (Ktrans), extracellular extravascular volume fraction (ve), and entropy values, as well as changes to each of these parameters, extracted from the second DCE-MRI scans, showed significant differences between the CR and PR groups. The area under the curve (AUC) of Ktrans, ve, and entropy values showed good diagnostic ability (0.813, 0.789, and 0.707, respectively). A logistic regression model combining Ktrans, ve, and entropy had significant diagnostic ability (AUC=0.977).ConclusionsThe use of a combined model with vascular permeability and texture parameters can improve post-NACRT prognostication in patients with ESCC.

scholarly journals Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models

2021 ◽  
Vol 49 (3) ◽  
pp. 030006052199758
Author(s):  
Hongwei Liang ◽  
Chunhong Hu ◽  
Jian Lu ◽  
Tao Zhang ◽  
Jifeng Jiang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Magnetic Resonance ◽  
Microvessel Density ◽  
Roc Analysis ◽  
Diagnostic Model ◽  
Model Parameters ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Quantitative Parameters ◽  
Contrast Enhanced

Objective To explore the correlations of radiomic features of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with microvessel density (MVD) in patients with hepatocellular carcinoma (HCC), based on single-input and dual-input two-compartment extended Tofts (SITET and DITET) models. Methods We compared the quantitative parameters of SITET and DITET models for DCE-MRI in 30 patients with HCC using paired sample t-tests. The correlations of SITET and DITET model parameters with CD31-MVD and CD34-MVD were analyzed using Pearson’s correlation analysis. A diagnostic model of CD34-MVD was established and the diagnostic abilities of models for MVD were analyzed using receiver operating characteristic curve (ROC) analysis. Results There were significant differences between the quantitative parameters in the two kinds of models. Compared with SITET, DITET parameters showed better correlations with CD31-MVD and CD34-MVD. The Ktrans and Ve radiomics features of the DITET model showed high efficiency for predicting the level of CD34-MVD according to ROC analysis, with areas under curves of 0.83 and 0.94, respectively. Conclusion Compared with SITET, the DITET model provides a better indication of the microcirculation of HCC and is thus more suitable for examining patients with HCC.

scholarly journals Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Xingchen Wu ◽  
Petri Reinikainen ◽  
Mika Kapanen ◽  
Tuula Vierikko ◽  
Pertti Ryymin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Early Diagnosis ◽  
Early Stage ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Transfer Constant ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

Background and Purpose. Although several methods have been developed to predict the outcome of patients with prostate cancer, early diagnosis of individual patient remains challenging. The aim of the present study was to correlate tumor perfusion parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and clinical prognostic factors and further to explore the diagnostic value of DCE-MRI parameters in early stage prostate cancer. Patients and Methods. Sixty-two newly diagnosed patients with histologically proven prostate adenocarcinoma were enrolled in our prospective study. Transrectal ultrasound-guided biopsy (12 cores, 6 on each lobe) was performed in each patient. Pathology was reviewed and graded according to the Gleason system. DCE-MRI was performed and analyzed using a two-compartmental model; quantitative parameters including volume transfer constant (Ktrans), reflux constant (Kep), and initial area under curve (iAUC) were calculated from the tumors and correlated with prostate-specific antigen (PSA), Gleason score, and clinical stage. Results. Ktrans (0.11 ± 0.02 min−1 versus 0.16 ± 0.06 min−1; p<0.05), Kep (0.38 ± 0.08 min−1 versus 0.60 ± 0.23 min−1; p<0.01), and iAUC (14.33 ± 2.66 mmoL/L/min versus 17.40 ± 5.97 mmoL/L/min; p<0.05) were all lower in the clinical stage T1c tumors (tumor number, n=11) than that of tumors in clinical stage T2 (n=58). Serum PSA correlated with both tumor Ktrans (r=0.304, p<0.05) and iAUC (r=0.258, p<0.05). Conclusions. Our study has confirmed that DCE-MRI is a promising biomarker that reflects the microcirculation of prostate cancer. DCE-MRI in combination with clinical prognostic factors may provide an effective new tool for the basis of early diagnosis and treatment decisions.

Sign in / Sign up

Export Citation Format

Share Document